Regencell Bioscience Holdings Limited
RGCHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeRegencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. The $3.80B market capitalization puts RGC squarely in mid-cap range for its industry. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Market Cap
$3.80B
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.02
EPS (Fwd)
—
ROE
-128.5%
ROA
-71.5%
Cash
$14.2M
Total Debt
$295,811
Free CF
-$3.0M
52W Change
-51.8%
Annual Financials
Cash vs Debt
Where RGC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, RGC finished 32.69% below its 150-day moving average ($14.93) and 45.50% below its 200-day moving average ($18.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RGC overbought or oversold?
At the October 20, 2026 close, RGC's RSI(14) was 85.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $14.2M in cash and $296K in debt, RGC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$3.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -128.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Regencell Bioscience Holdings Limited's trajectory.